IP Verse

Murphy, Colm Damien opposition analysis

COMPANY ANALYSIS

Patent Number:

Title:

Methods And Formulations Which Allow The Modulation Of Immune Responses Related To The Administration Of A Biopharmaceutical Drug

Applicant:

Opposition Date:

Mar 26, 2019

Patent Number:

Title:

Crispr-Based Genome Modification And Regulation

Applicant:

Opposition Date:

Jun 20, 2018

Patent Number:

Title:

Fgfr3 Fusion Gene And Pharmaceutical Drug Targeting Same

Applicant:

Opposition Date:

Jun 13, 2018

Patent Number:

Title:

Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance

Applicant:

Opposition Date:

Feb 2, 2018

Patent Number	Title	Applicant	Opposition Date
EP3021833	Methods And Formulations Which Allow The Modulation Of Immune Responses Related To The Administration Of A Biopharmaceutical Drug	HEXAL AKTIENGESELLSCHAFT	Mar 26, 2019
EP3138910	Crispr-Based Genome Modification And Regulation	SIGMA-ALDRICH CO. LLC	Jun 20, 2018
EP2902489	Fgfr3 Fusion Gene And Pharmaceutical Drug Targeting Same	CHUGAI SEIYAKU KABUSHIKI KAISHA	Jun 13, 2018
EP2552955	Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance	CHUGAI SEIYAKU KABUSHIKI KAISHA	Feb 2, 2018

CHUGAI SEIYAKU KABUSHIKI KAISHA

HEXAL AKTIENGESELLSCHAFT

SIGMA-ALDRICH CO. LLC

Feel free to send us a message here and we will get back to you